Iktos

Iktos is a pioneering AI-native drug discovery company building an integrated, automated platform to radically shorten the early-stage R&D timeline. Its core technology combines the generative AI software Makya for molecular design, the retrosynthesis AI Spaya for synthesis planning, and proprietary robotics systems for automated chemical synthesis and biological testing. This closed-loop Design-Make-Test-Analyze (DMTA) cycle enables rapid iteration and optimization of drug candidates. The company validates its platform through both external collaborations with major pharma partners and an internal pipeline of proprietary programs targeting challenging biological mechanisms.

Integrated platform combining generative AI for molecular design (Makya), AI for retrosynthesis planning (Spaya), and proprietary robotics systems for automated chemical synthesis, purification, analysis, and biological testing. This creates a closed-loop, AI-driven Design-Make-Test-Analyze (DMTA) cycle.

Iktos operates in the competitive AI drug discovery space, competing with pure-play AI software companies (e.g., Insilico Medicine), integrated AI/biotech firms (e.g., Exscientia, Recursion), and large tech entrants. Its key differentiator is the deep integration of generative AI with proprietary, end-to-end laboratory robotics for physical synthesis and testing.